Document is current
Any future updates will be listed below
-
Authors
England, James T. https://orcid.org/0000-0002-9692-1634
Szuber, Natasha
Sirhan, Shireen https://orcid.org/0000-0003-4957-4307
Dunne, Tom
Cerquozzi, Sonia
Hill, Madeleine https://orcid.org/0009-0008-0082-4559
Villeneuve, Pierre J. A. https://orcid.org/0000-0002-0944-1721
Ho, Jenny M.
Sadikovic, Bekim
Bhai, Pratibha
Krishnan, Nupur
Dowhanik, Sebastian
Hillis, Chris
Capo-Chichi, Jose-Mario
Tsui, Hubert
Cheung, Verna
Gauthier, Karine
Sibai, Hassan
Davidson, Marta B.
Bankar, Aniket
Kotchetkov, Rouslan
Gupta, Vikas https://orcid.org/0000-0002-1419-8607
Maze, Dawn https://orcid.org/0000-0002-4598-9380
-
Funding
Funding for this research was provided by:
Princess Margaret Cancer Foundation
Tony and Elizabeth Comper Foundation
- License Information
-
More Information
Article History
Received: 17 August 2023
Revised: 27 December 2023
Accepted: 11 January 2024
First Online: 6 February 2024
Competing interests
: JTE, NS, SS, TD, SC, MH, PJAV, JMH, BS, PB, NK, SD, CH, JMCC, HT, VC, KG, HS, MBD, AB, and RK report no conflicts or competing interests to declare. VG has received research funding through his institution and honoraria from Novartis and Incyte and has served on the advisory board of Novartis, Incyte, BMS-Celgene, Abb Vie, Sierra Oncology, Pfizer, Takeda, and Constellation Biopharma. DM has received search support from Novartis, Celgene/BMS, PharmaEssentia, Takeda; honoraria from Novartis, Celgene/BMS; and has served in consultation or on the advisory board for Novartis and Pfizer.
